Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1102 in non-ambulatory Duchenne Muscular Dystrophy
NCT05938023Phase 2Terminated
- Sponsor
- Percheron Therapeutics
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 2 trial of avicursen in Duchenne muscular dystrophy (DMD), sponsored by Percheron Therapeutics. Started May 2023; status: terminated.
02
Drugs
avicursen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05938023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938023.